Recent Updates
Recently added Catalysts

ZIO-101-C

Phase 1

Advanced Cancer | Small molecule | Oncology |Alaunos Therapeutics, Inc.|Last Updated: Sep 29, 2026

Target and mechanism

ModalitySmall molecule

Also known as ZIO-101-C (Darinaparsin)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment23

FDA Designations

No designations recorded

Clinical trial landscape

ZIO-101-C · 2 trials · 3 indications

Phase 1 2
NCT00592163Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasAdvanced Solid Tumors
COMPLETED20 Analytics
NCT00591422Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasAdvanced Cancer
COMPLETED23 Analytics
PHASE1COMPLETED
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Advanced Solid Tumors
NCT0059216320
Unlock trial analytics
PHASE1COMPLETED
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Advanced Cancer
NCT0059142223
Unlock trial analytics

Study Endpoints

Primary Endpoints

toxicities
6 months

Secondary Endpoints

pharmacokinetics
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single ArmEXPERIMENTAL -

Interventions

NameTypeDescription
ZIO-101-C (Darinaparsin)DRUGDose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: 1. Subjects with histological or cytological confirmation of advanced cancer that is refractory to standard therapies for their condition. 2. Men and women of ≥18 years of age. 3. ECOG performance score ≤2. 4. Eligible subjects MUST have at least one measurable lesion as defined...

Countries:CanadaUnited States
Unlock Eligibility Criteria

Competitive Landscape -Cancer 5 trials (matched to "Advanced Cancer")

Top 2 of 3 competitors

CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520/GEH200521
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence

Explore more on BiopharmaWatch

Alaunos Therapeutics, Inc. (TCRT)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ZCompanies A to ZEvery biotech and pharma company we track